Multifaceted World of Chemically Modified Oligonucleotides for Nucleic Acid Therapeutics
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: 20 December 2024 | Viewed by 3317
Special Issue Editor
2. Laboratory of Nucleic Acid Chemistry, Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia
Interests: nucleic acid chemistry; design of DNA and RNA analogues; oligonucleotide synthesis; modification and conjugation; oligonucleotide therapeutics; nucleic acid drug delivery; DNA nanotechnology
Special Issue Information
Dear Colleagues,
The year 2023 marks the twin anniversary of nucleic acid therapeutics, i.e., 45 years since the publication (1978) of the celebrated paper written by Paul Zamecnik and Mary Stephenson, which heralded the advent of antisense technology, and 25 years since the approval of the first oligonucleotide drug, Vitravene (fomivirsen), in 1998. However, as 2023 nears the end, I believe another paper ought to be recalled: an early work by Nina Grineva et al. that appeared 55 years ago (Belikova et al., 1967, PMID 6073336). For the first time, it put forward the idea of exploiting the sequence-selective Watson–Crick duplex formation between an oligonucleotide and its complementary nucleic acid target (DNA in the paper) to achieve a therapeutic effect. Oligonucleotide synthesis was still in its infancy at that moment, although the same year (1967), Fritz Eckstein described the synthesis of the first ever enzymatically resistant phosphate mimic, replacing one of the nonbridging oxygen atoms of the phosphodiester group with sulfur—a dinucleoside phosphorothioate that, decades later, gave rise to first-generation antisense oligonucleotides such as fomivirsen. Consequently, it took over ten years for the Grineva concept to be experimentally verified in Zamecnik’s study, which firmly identified the biological target of antisense oligonucleotides to be an RNA molecule (mRNA in that case). At long last, chemically modified oligonucleotides received nearly universal recognition as precision tools for antisense- and RNAi-based gene therapies and more (e.g., mRNA vaccines, CRISPR/Cas, etc.). Every year since 2016 up until now, one, two or even three of these drugs would enter the pharmaceutical market, the latest being the siRNA Amvuttra (vutrisiran) in June 2022, and the morpholino antisense Amondys 45 (casimersen) in February 2021.
The aim of this Special Issue is to provide a snapshot of contemporary modified oligonucleotides, as well as their design, synthesis and applications as potential therapeutics. Suitable topics include, but are not limited to, oligonucleotides (including gapmers) with various phosphate/sugar/nucleobase modifications and terminal pendant groups, 2′-O-alkyl RNAs, bridged/locked nucleic acids (B/LNAs), peptide nucleic acids (PNAs), phosphorodiamidate morpholino oligonucleotides (PMOs), etc., cell/tissue-deliverable peptides, lipid and polymer/dendrimer conjugates, oligonucleotide-functionalized nanoparticles (spherical nucleic acids (SNAs), etc.), DNAzymes, DNA/RNA aptamers, CpG oligonucleotides, and therapeutic applications thereof, including genetic disorders/splice switching, neurodegenerative, cardiovascular and metabolic diseases, anticancer, antiviral, antibacterial, immunomodulatory, etc.
Dr. Dmitry A. Stetsenko
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- DNA and RNA analogues
- phosphate mimics
- sugar-modified oligonucleotides
- base modifications
- nucleic acid therapeutics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
